Paper39842011
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.
Ruff CT and 19 others. N Engl J Med, 2025. Cited by 94 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. Papers, record 39842011. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39842011
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal, Humanized | Major topic |
| Anticoagulants | Major topic |
| Atrial Fibrillation | Major topic |
| Factor Xa Inhibitors | Major topic |
| Hemorrhage | Major topic |
| Rivaroxaban | Major topic |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Administration, Oral | |
| Double-Blind Method | |
| Factor XI | |
| Injections, Subcutaneous | |
| Stroke | |
| Incidence | |
| Severity of Illness Index | |
| Follow-Up Studies | |
| Treatment Outcome |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04755283 | Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation | Results | Yes |
Source ClinicalTrials.gov
Comments and corrections3
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 40,239,081 | Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. | https://conductscience.org/library/papers/40239081 | PubMed |
| Comment in | 40,239,082 | Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. | https://conductscience.org/library/papers/40239082 | PubMed |
| Comment in | 40,239,083 | Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. Reply. | https://conductscience.org/library/papers/40239083 | PubMed |
Cited by61
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 94 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,964,437 | Warfarin After Seven Decades: Persistent Value and the Contemporary Role of Vitamin K Antagonism. | Cardiol Res | 2026 | https://conductscience.org/library/papers/42964437 | PubMed |
| 42,961,609 | Safety, Pharmacokinetics, and Pharmacodynamics of SHR-2004, a Novel Humanized Monoclonal Antibody Targeting Factor XI, in Patients with Atrial Fibrillation: An Open-Label Phase 1b Study. | Clin Pharmacokinet | 2026 | https://conductscience.org/library/papers/42961609 | PubMed |
| 42,939,623 | Direct Oral Anticoagulants in the Cardiorenal Patient: Pharmacology, Kidney Function Estimation and Dose Selection Across the CKD Spectrum. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42939623 | PubMed |
| 42,936,593 | Evaluating the potential of factor XI/factor XIa inhibitors to address unmet anticoagulation needs in critical patient populations. | Res Pract Thromb Haemost | 2026 | https://conductscience.org/library/papers/42936593 | PubMed |
| 42,936,574 | Measuring up: the need for new assays for factor (F)XI/FXIa inhibitor therapies. | Res Pract Thromb Haemost | 2026 | https://conductscience.org/library/papers/42936574 | PubMed |
| 42,936,046 | Perspectives: what we are learning from factor XI/factor XIa inhibitor trials. | Res Pract Thromb Haemost | 2026 | https://conductscience.org/library/papers/42936046 | PubMed |
| 42,923,502 | 2026 Asia Pacific Heart Rhythm Society (APHRS) Guidelines (Part II) on Stroke Prevention in Atrial Fibrillation. | J Arrhythm | 2026 | https://conductscience.org/library/papers/42923502 | PubMed |
| 42,898,680 | Beyond traditional anticoagulants: exploring the future of thromboembolism treatment with FXI inhibitors. | Front Immunol | 2026 | https://conductscience.org/library/papers/42898680 | PubMed |
| 42,897,704 | Atrial fibrillation in stroke patients: facts, numbers and current challenges. | Neurol Res Pract | 2026 | https://conductscience.org/library/papers/42897704 | PubMed |
| 42,888,464 | FXI and FXII in experimental stroke and FXI in clinical stroke trials. | Neurol Res Pract | 2026 | https://conductscience.org/library/papers/42888464 | PubMed |
| 42,881,892 | Factor XI and XIa Inhibitors: A State-of-the-Art Review Across Clinical Indications. | J Clin Med | 2026 | https://conductscience.org/library/papers/42881892 | PubMed |
| 42,876,548 | Personalized anticoagulant therapy in venous thromboembolism: current role of direct oral anticoagulants, unmet clinical needs, and future perspectives on Factor XI inhibition. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42876548 | PubMed |
| 42,870,289 | Anticoagulation-associated hemorrhage in atrial fibrillation as a marker of occult malignancy: a narrative review. | Thromb J | 2026 | https://conductscience.org/library/papers/42870289 | PubMed |
| 42,847,068 | Factor XI(a) Inhibition in Secondary Stroke Prevention: On the Cusp of a New Anticoagulation Paradigm. | ACS Pharmacol Transl Sci | 2026 | https://conductscience.org/library/papers/42847068 | PubMed |
| 42,828,316 | A New Paradigm for Precision Medicine in Heatstroke: From Molecular Subtyping to Targeted Prevention and Treatment. | J Inflamm Res | 2026 | https://conductscience.org/library/papers/42828316 | PubMed |
| 42,795,953 | Coronary Artery Disease and Atrial Fibrillation in HighBleeding Risk: Indications and Optimal Antithrombotic Therapy After Percutaneous Left Atrial Appendage Occlusion. | J Clin Med | 2026 | https://conductscience.org/library/papers/42795953 | PubMed |
| 42,628,751 | Structural insights into the exosite-mediated activation of factor IX by factor XIa using cryogenic electron microscopy. | J Thromb Haemost | 2026 | https://conductscience.org/library/papers/42628751 | PubMed |
| 42,599,041 | Factor XI Inhibition for Ischemic Stroke Secondary Prevention: Pharmacology, Clinical Evidence, and Future Directions. | J Clin Pharmacol | 2026 | https://conductscience.org/library/papers/42599041 | PubMed |
| 42,590,048 | Anticoagulation Stewardship in the Era of Practice-Changing Evidence: A Narrative Review of Recent Trials and Their Bedside Translation. | J Clin Med | 2026 | https://conductscience.org/library/papers/42590048 | PubMed |
| 42,275,249 | Anticoagulation with the mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat). | Blood | 2026 | https://conductscience.org/library/papers/42275249 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| ABELACIMAB | CHEMBL4650369 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL4650369 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39842011
GET https://conductscience.org/api/papers/v1/39842011/cited_by?page=2